Spiriva

Report
33 Pages
July 2018
Region: Global
Citeline
ID: 4533473

Drug Overview
Spiriva (tiotropium; Boehringer Ingelheim) is a long-acting muscarinic antagonist (LAMA) approved for use in chronic obstructive pulmonary disease (COPD), and is available in a dry-powder inhaler (HandiHaler) and soft mist inhaler (Respimat) device. Spiriva exhibits pharmacological effects in the airways through inhibition of M1 and M3 receptors at the smooth muscle, leading to bronchodilation. It is indicated for the long-term treatment of COPD-associated bronchospasm and for the management of exacerbations. Spiriva was the first LAMA on the market, making it the gold-standard monotherapy in COPD. It is also approved for use in asthma.

OVERVIEW

Drug Overview
Product Profiles
Spiriva: Chronic obstructive pulmonary disease (COPD)
Spiriva: Asthma

LIST OF FIGURES

Figure 1: Spiriva for COPD – SWOT analysis
Figure 2: The authors drug assessment summary of Spiriva for COPD
Figure 3: The authors drug assessment summary of Spiriva for COPD
Figure 4: Spiriva sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Spiriva for asthma – SWOT analysis
Figure 6: The authors drug assessment summary of Spiriva in asthma
Figure 7: The authors drug assessment summary of Spiriva in asthma
Figure 8: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES

Table 1: Spiriva drug profile
Table 2: Spiriva HandiHaler Phase III data in COPD
Table 3: Spiriva Respimat Phase III data in COPD
Table 4: Spiriva Respimat’s long-term Phase III TIOSPIR study against Spiriva HandiHaler
Table 5: Spiriva sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 6: Spiriva drug profile
Table 7: Spiriva pivotal trial data in asthma
Table 8: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017–26

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9730EUR$10,000USD£8,335GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€47676EUR$49,000USD£40,842GBP

Table of Contents

Related Topics

Related Reports

COPD in America 2023: Key Insights into Treatment Awareness & Satisfaction

COPD in America 2023: Understanding the COPD Patient Experience

Dry Powder Inhaler Global Market Report 2024

Reversible Airway Diseases Treatment Global Market Report 2024

Pulmonary / Respiratory Drug Delivery - Global Strategic Business Report